Back to results
US 12,385,894 B2Granted
Systems and methods for characterizing surfactant protein D (SP-D) oligomers
AssigneeAirway Therapeutics, Inc.
InventorsJan Susan Rosenbaum, Mark Cornell Manning, Ryan R. Manning
Life of this patent
Estimating the term…
Abstract
Some embodiments of the methods and compositions provided herein include identifying and/or quantifying oligomeric species of surfactant protein-D (SP-D). Some embodiments include performing an asymmetric flow field-flow fractionation with multi-angle laser light scattering (AF4-MALLS) analysis on the SP-D.
Claims11
A method to determine the activity of a pharmaceutical composition comprising surfactant protein-D (SP-D), the method comprising:
- measuring the relative proportion of oligomeric species of SP-D in the pharmaceutical composition;
- and
- calculating the relative proportion of SP-D dodecamers in the pharmaceutical composition, thereby determining the activity of the pharmaceutical composition,
- wherein
- the activity comprises activity in a toll-like receptor 4 (TLR4) assay,
- the calculating comprises providing a model of the oligomeric species of the SP-D comprising rod-like geometries and spherical-like geometries,
- the model comprises a Zimm model and a second order Debye model of the oligomeric species of the SP-D, and
- the pharmaceutical composition having a relative proportion of SP-D dodecamers greater than or equal to 20% of the SP-D oligomeric species is indicative of the pharmaceutical composition having activity in the TLR4 assay.
5 more elements
A method to determine the relative proportion of oligomeric species of surfactant protein-D (SP-D) in a sample, comprising:
- performing an asymmetric flow field-flow fractionation with multi-angle laser light scattering (AF4-MALLS) analysis on the SP-D sample;
- determining the relative proportion of an oligomeric species of SP-D from the results of the AF4-MALLS analysis, wherein the SP-D oligomeric species is selected from the group consisting of a SP-D trimer, a SP-D hexamer, a SP-D dodecamer, a SP-D starlike oligomer having an average radius of 70 nm or RMS radius of 70 nm, and SP-D aggregate having an average radius greater than 70 nm or RMS radius greater than 70 nm, and differentiating the species using a Zimm model for rod-like geometries and a Debye model for spherical-like geometries, and
- measuring the relative proportion of SP-D dodecamers in the sample,
- wherein the sample having a relative proportion of SP-D dodecamers greater than or equal to 20% of the SP-D oligomeric species is indicative of the pharmaceutical composition having activity, and wherein the activity comprises activity in a toll-like receptor 4 (TLR4) assay.
1 more element
Dependencies are inferred from the claim text.